Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Defective Lipoprotein Binding in the Brain Linked to Alzheimer's Disease Risk

By LabMedica International staff writers
Posted on 03 Aug 2016
Mutations in the TREM2 (Triggering receptor expressed on myeloid cells 2) gene, which encodes a protein expressed selectively by microglia in the brain, have been linked to disrupted binding of lipoproteins and are associated with the development of Alzheimer’s disease (AD). More...


Previous studies had shown that microglia - immune cells that remove pathogenic materials from the brain in a manner similar to that of microphages in the immune system - from individuals with TREM2 mutations had decreased ability to bind to lipoproteins in the brain's extracellular milieu.

To study this phenomenon further, investigators at the biotech company Genetech (South San Francisco, CA, USA) performed a large unbiased screen of an extracellular recombinant protein library representing 1,559 extracellular proteins and identified a set of lipoprotein particles and apolipoproteins as ligands of TREM2.

They reported in the July 20, 2016, issue of the journal Neuron that the TREM2 ligands included the apolipoproteins APOE and CLU (APOJ), which are risk genes for AD, and that their binding was impaired by TREM2 mutations that conferred AD risk. Binding of these ligands by TREM2 was abolished or reduced by disease-associated mutations.

Overexpression of wild-type TREM2 was sufficient to enhance uptake of LDL, CLU, and APOE in heterologous cells, whereas TREM2 disease variants were impaired in this activity. Amyloid-beta was found to be bound to lipoproteins, and this complex was efficiently taken up by microglia in a TREM2-dependent fashion. Uptake of Amyloid-beta-lipoprotein complexes was reduced in macrophages from human subjects carrying a TREM2 AD variant. In addition, the investigators provided evidence that, through its interaction with lipoproteins, TREM2 could facilitate Amyloid-beta uptake by microglia and human macrophages.

"I think we are only scratching the surface of what TREM2 does," said senior author Dr. Morgan Sheng, vice-president of neuroscience at Genentech. "Lipoproteins float around in the blood, and their purpose is to carry cholesterol or lipids from one cell to another - as we all know, too much LDL is associated with high cholesterol and increased risk of cardiovascular disease. Lipoproteins also exist in the brain, but less is understood about their role there. "

"Overall, these studies further point towards microglia as playing an important role in the pathogenesis of Alzheimer's disease," said Dr. Shen. "It was a surprise that amyloid-beta was much more efficiently engulfed when bound in a lipoprotein complex, rather than when amyloid-beta aggregates were free and naked."

Related Links:
Genetech



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Nasopharyngeal Applicator
CalgiSwab 5.5" Sterile Mini-tip Calcium Alginate Nasopharyngeal Swab w/Aluminum HDLE
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.